<DOC>
	<DOC>NCT01506336</DOC>
	<brief_summary>The objective is to compare efficacy and safety of masitinib at 12 mg/kg/day to sunitinib at 50 mg/day in treatment of patients with gastro-intestinal stromal tumor resistant to imatinib.</brief_summary>
	<brief_title>A Phase 2 Study to Evaluate Efficacy and Safety of Masitinib in Comparison to Sunitinib in Patients With Gastro-Intestinal Stromal Tumour Resistant to Imatinib</brief_title>
	<detailed_description />
	<mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>1. Histological proven, metastatic, or locally advanced and nonoperable GIST 2. Measurable tumor lesions with longest diameter ≥ 20 mm using conventional techniques or ≥ 10 mm with spiral CT scan according RECIST criteria 3. Ckit (CD117) positive tumors detected immunohistochemically and documented mutation of ckit at any time if available 4. Patients resistant to imatinib at dose of 400 mg/day 1. Patient treated for a cancer other than GIST cancer within 5 years before enrolment, with the exception of basal cell carcinoma or cervical cancer in situ 2. Patient with active central nervous system (CNS) metastasis or with history of CNS metastasis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>GIST</keyword>
	<keyword>resistant</keyword>
	<keyword>imatinib</keyword>
	<keyword>gastro intestinal stromal tumor resistant to imatinib</keyword>
</DOC>